The department’s research programs consist of four major areas: Cardiovascular molecular medicine, molecular imaging, molecular genetics, and molecular tumor medicine.

We’re now carrying out studies to enhance the level of medical research and to improve domestic health care problems.  

A. Molecular Cardiovascular Medicine 

Free radicals, molecular genetics and gene therapy, pathophysiology of cardiovascular disease (heart failure, hypertension, atherosclerosis and cardiac arrhythmias, etc.), traditional Chinese medicine in cardiovascular medicine applications, and development of experimental animal models are five areas as teaching and research focus

B. Molecular image

Molecular imaging is a rapidly emerging field, providing noninvasive visual quantitative representations of fundamental biological processes in intact living subjects. Fundamental biomedical research stands to benefit considerably from advances in molecular imaging, with improved molecular target selection, probe development and imaging instrumentation. The noninvasiveness of molecular imaging technologies will also provide benefit through improved patient care. Molecular imaging endpoints can be quantified, and therefore are particularly useful for translational research. Integration of the two disciplines of molecular imaging and molecular medicine, combined with systems-biology approaches to understanding disease complexity, promises to provide predictive, preventative and personalized medicine that will transform healthcare. In the past, our researches are focused on developing several novel approaches, such as novel molecular probes and reporter genes, in the molecular-genetic imaging, molecular-targeting imaging, in vivo cell trafficking imaging and in vivo molecular interaction imaging. These approaches will be to provide the potential for: (i) understanding a living subject abnormal biology in a more rapid and noninvasive manner, and with less labour than is the case with conventional pathology- or clinical chemistry-based assays; (ii) earlier detection and characterization of disease and its pathogenesis and (iii) rapid assessment of therapeutic effectiveness at a molecular level, long before phenotypic change. In the future, we will propose to utilize these developed approaches to investigate the molecular pathology and to create the imaging tool for early diagnosis in cancer, cardiovascular disease, neurosciences and    inflammation diseases.    

C. Molecular genetics 

  1. Diagnosis of genetic diseases: gene mutation analysis, identification of genes associated with disease, regulation of gene expression, protein - gene interactions, gene therapy, and improvement of biochemical technology and assay system.
  2. Cytogenetics: chromosomal disorder diagnosis, fluorescent in situ hybridization (FISH) diagnosis of genetic diseases and chromosomal abnormalities.
  3. Biochemical genetics: biochemical analysis of congenital metabolic diseases, , development of mass spectrometry methods applied to the study of metabolic diseases, development of new neonatal screening items and improvement of screening accuracy
  4. Functional Genomics: transgenic technology, gene transfer vectors and vehicles, functional study using transgenic cell or animals, mechanism and regulation of gene expression, epigenetic regulation, gene splicing and alternative RNA splicing, anti-sense interference Micro-RNA regulation, stem cell medicine, cell-based and gene-based therapy translational research.
  5. Proteomics: establishment of the first Proteomics Center in central Taiwan with major emphasis on identification of disease-related proteins and the establishment of a proteomics database.

D. Tumor Molecular Medicine

  1. Promote tumor genomics research and treatment, in order to find more cancer-related gene or tumor suppressor genes.
  2. Development of the modernization of traditional medicine as a method of tumor diagnosis and treatment. Establishment of a high-performance platform for drug screening in order to effectively filter out the precursor of anti-cancer drugs and further pharmacology and pharmacokinetics of studies to examine and assess the possibility fof using as a clinical treatment.
  3. Oral cancer, nasopharyngeal cancer, liver cancer, esophageal cancer, lung cancer, breast cancer, leukemia and lymphoma are the major focus of this program.